2-TIP QANDLI DIABET PATOGENEZIDA AUTOFAGIYA JARAYONINING ROLI VA INTERVAL OCHLIKNING BIOKIMYOVIY KORREKSIYASI

Type 2 diabetes (T2DM) is driven in part by dysfunction at the cellular level, not just by blood sugar mismanagement. This study, published in Uzbek, investigates how a key cellular 'housekeeping' process called autophagy — by which cells break down and recycle damaged components — becomes blocked in T2DM. The blockade appears to result from chronic high insulin levels (hyperinsulinemia) over-activating a protein called mTOR, which acts as a master brake on autophagy. The researchers propose that intermittent fasting on a 16:8 schedule (16 hours fasting, 8 hours eating) can reactivate autophagy by switching on a competing protein called AMPK, effectively flipping a 'metabolic switch.' A notable claim is that 16–18 hours of fasting can help break down toxic amyloid protein aggregates that build up in the insulin-producing beta cells of the pancreas, potentially reducing insulin resistance at a biochemical level. The authors argue this 'cytocentric' (cell-focused) approach could reduce the need for medications and even help achieve disease remission in some patients. The work positions dietary fasting as a mechanistically grounded intervention rather than a lifestyle suggestion, though the evidence tier is classified as emerging.

• Chronic hyperinsulinemia drives excessive mTOR pathway activation, which the study identifies as a primary mechanism for autophagy blockade in T2DM beta cells.
• A 16:8 intermittent fasting protocol is reported to activate AMPK signalling and initiate a 'metabolic switch' that restores autophagic flux.
• 16–18 hours of fasting is reported to be sufficient to degrade amyloid aggregates in pancreatic beta cells, with the authors linking this directly to biochemical correction of insulin resistance and a potential pathway to T2DM remission.

This appears to be a narrative or mechanistic review study — potentially including a human intervention component involving a 16:8 intermittent fasting protocol — synthesising biochemical and clinical data on mTOR/AMPK signalling and autophagy in T2DM patients. The abstract does not explicitly state sample size, control group design, or duration of follow-up, so precise study architecture cannot be confirmed from available metadata. Methods characterisation here is best-effort given abstract-level information only; full methodology requires access to the primary Uzbek-language text.

The abstract does not report sample size, control conditions, or follow-up duration, making it impossible to evaluate effect size reliability or generalisability from the summary alone. It is unclear whether the amyloid aggregate clearance and AMPK activation findings are derived from human participants, animal models, or in-vitro systems, which substantially affects clinical translation confidence. The study's language (Uzbek) and publication venue (Zenodo preprint repository) mean it has not undergone confirmed peer review at the time of indexing. A controlled randomised trial with biopsy-confirmed autophagy flux markers and standardised fasting adherence monitoring would be the logical next step to validate these mechanistic claims.

This article extends [§39], which examines AMPK activation as a therapeutic target in metabolic dysfunction-associated steatotic liver disease using metformin-phytochemical combinations — both studies converge on AMPK as the central node linking fasting or pharmacological intervention to autophagic restoration, but differ in organ target and intervention modality. It parallels [§130], which investigates intermittent fasting's regulatory impact on autophagy in a high-fat-diet brain deterioration model, reinforcing the cross-tissue relevance of fasting-induced autophagic rescue across metabolic disease contexts. The mTOR signalling focus also places this work in conversation with [§62], which interrogates PI3K/AKT/mTOR pathway suppression in renal cell carcinoma — illustrating that mTOR-mediated autophagy blockade is a shared pathological mechanism across metabolically distinct diseases, though the therapeutic implications diverge significantly. The aggregate-clearance framing echoes [§37], which demonstrates autophagic clearance of protein aggregates via GABARAPs, supporting the broader corpus theme that restoring autophagic flux is a viable strategy against proteotoxic cellular stress. Confidence in corpus placement is moderate given that full methods and data tables from this Uzbek-language preprint were not accessible for direct comparison.

• Metformin-phytochemical combination therapy in metabolic dysfunction-associated steatotic liver disease: mechanistic insights and therapeutic potential
  Most direct mechanistic parallel: both target AMPK activation to restore metabolic homeostasis, but [id=39] uses metformin-phytochemical combinations in liver disease rather than dietary fasting in T2DM, allowing direct comparison of pharmacological vs. non-pharmacological AMPK activation strategies.
• Regulatory impact of intermittent fasting on autophagy in high fat diet induced structural and cognitive brain deteriorations in rats
  Both studies test intermittent fasting as an autophagy-inducing intervention, but [id=130] measures outcomes in brain tissue under high-fat diet conditions, providing a useful cross-tissue comparison of the same dietary protocol.
• CHCHD2 and CHCHD10 promoted autophagic clearance of protein aggregates via GABARAPs
  Directly relevant mechanistic complement: [id=37] characterises how GABARAP-family proteins mediate autophagic clearance of protein aggregates, which could mechanistically underpin the amyloid aggregate degradation in beta cells that this study reports.
• Mammalian Lysophagy: mechanisms and pathophysiological implications
  [id=38] covers mammalian lysophagy mechanisms and their pathophysiological implications, offering deeper organelle-level context for understanding how autophagy flux restoration — as proposed here — proceeds at the lysosomal clearance step.
• Mechanism of Inonotus hispidus in suppressing renal cell carcinoma proliferation via regulation of the PI3K/AKT/mTOR pathway
  Contrasting disease context with shared pathway: [id=62] examines mTOR suppression in renal cell carcinoma via PI3K/AKT/mTOR, enabling readers to contrast how mTOR inhibition serves opposite therapeutic goals (anti-proliferative vs. metabolic rescue) depending on cellular context.